This site is intended for health professionals only

Wednesday 19 June 2019
LatestNews
Share |

Latest News

Lynparza approved for first-line maintenance treatment of BRCA-mutated advanced ovarian cancer

Tuesday 18th June 2019
AstraZeneca and MSD have announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.
 
The licensed indication is as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (...
Sun, 16 Jun 2019
Study also reveals venous thromboembolism and epilepsy as potential novel comorbidities
Sat, 15 Jun 2019
Initial pilot data support the use of new neurostimulation treatment in a larger study in patients who have failed current standard of care
Fri, 14 Jun 2019
In the European Union alone, an extra one million employees could be in work each day if early interventions were more widely accessible for people with rheumatic and musculoskeletal diseases (RMDs)
Fri, 14 Jun 2019
Over half of patients and rheumatologists report diagnosis within six weeks as the most problematic standard of care
Fri, 14 Jun 2019
Huge impact of pain and sleep on mental health raises questions about the level of care offered to patients
Thu, 13 Jun 2019
Pixantrone has been available to patients since 2012 following a conditional approval in Europe
Thu, 13 Jun 2019
Study reports no vaccine infections in children given live-attenuated booster vaccine while on immune suppressing therapies